Inflammatory Bowel Disease Treatment Market: Information by Drug Class (TNF Inhibitors, Aminosalicylates) Disease Indication (Ulcerative Colitis, Crohn’s Disease) Distribution Channel (Hospital Pharmacy), End-User (Hospitals & Clinics)—Forecast till 2023

Market Scenario

The inflammatory bowel disease treatment market is expected to register a CAGR of 2.5% during the forecast period. Inflammatory bowel disease is characterized by chronic inflammation of the digestive tract. It is an umbrella term for ulcerative colitis and Crohn’s disease. The market for inflammatory bowel disease treatment is growing worldwide due to factors such as the increasing prevalence of ulcerative colitis and Crohn’s disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, increasing number of drugs in clinical trial and growing popularity of probiotic and prebiotic foods is likely to spur market growth. However, high capital investments required for drug discovery, unsatisfactory effectiveness of treatment, and stringent drug regulatory policies are restraining the growth of the inflammatory bowel disease treatment market.

Market Segmentation

The global inflammatory bowel disease treatment market has been segmented on the basis of drug class, disease indication, distribution channel, and end-user. Based on drug class, the market has been segmented into TNF inhibitors, aminosalicylates, immunomodulators, and corticosteroids.

By disease indication, the market has been segmented into ulcerative colitis and Crohn’s disease.

By distribution channel, the market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

By end-user, the market has been segmented into hospitals and clinics and others.

Based on region, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has been further segmented into North America and South America. The European market has been further divided into Western Europe and Eastern Europe.

Regional Market Summary

Americas is expected to be the largest inflammatory bowel disease treatment market, by region. The increasing prevalence of anxiety and gluten allergies and inclination towards junk food has led to the increasing number of patients suffering from inflammatory bowel disease in the region. According to the Anxiety and Depression Association of America, anxiety was the most diagnosed mental disorder in the US, with around 40 million people, aged over 14, affected by anxiety every year. As per the Centers for Disease Control and Prevention (CDC), about 1.3% of US adults, approximately 3 million, were diagnosed with IBD, either Crohn’s disease or ulcerative colitis, in 2015. Furthermore, rising health awareness, the presence of key players, and established healthcare infrastructure are likely to enhance the growth of the inflammatory bowel disease treatment market in the region. According to the Centers for Medicare and Medicaid Services (CMS) in 2016, healthcare spending in the US increased by 4.3% to reach USD 3.3 trillion. Thus, increasing per capita income and rising healthcare spending will aid market growth in the Americas.

Europe was the second-largest inflammatory bowel disease treatment market, by region in 2017. The European market is expected to exhibit steady growth during the forecast period owing to the increasing prevalence of inflammatory bowel disease, rising rate of alcohol abuse, unhealthy lifestyle habits, and the increasing incidence of anxiety and depression among adults. Additionally, factors such as increasing government initiatives and funding for research, the development of advanced medical treatment options, and availability of favorable reimbursement policies are likely to propel the growth of the inflammatory bowel disease treatment market in Europe.

Asia-Pacific is expected to be the fastest-growing inflammatory bowel disease treatment market with an exponential rise in patient population. Japan and China are expected to be the largest markets for inflammatory bowel disease treatment in Asia-Pacific. The rising prevalence of anxiety and depression among adults as well as the increasing abuse of alcohol and sedentary lifestyles are expected to result in a growing patient pool, fueling the demand for treatment drugs. Furthermore, comparatively lenient drug regulatory policies and increasing government initiatives for
healthcare reform are expected to propel market growth during the forecast period. Rising healthcare expenditure and rising standards of living in the region are also driving the growth of the inflammatory bowel disease treatment market in Asia-Pacific.

The market in the Middle East & Africa is expected to show the least growth due to a lack of awareness about the disease, limited access to and availability of treatment facilities, and lower prevalence of the disorder. However, the market may grow in the UAE, Kuwait, and Saudi Arabia.

**Market Players**
- Abbott Laboratories
- Valeant Pharmaceuticals International
- Novartis AG
- Janssen Biotech, Inc.
- Alkem Laboratories Limited
- AbbVie, Inc.
- UCB Inc
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- Pfizer Inc.
- Allergan plc

**Global Inflammatory Bowel Disease Treatment Market Share, by Region, 2017 (%)**


**Market Segmentation and Key players**

**Global Inflammatory Bowel Disease Treatment Market, by Drug Class**
- TNF Inhibitors
- Aminosalicylates
- Immunomodulators
- Corticosteroids

**Global Inflammatory Bowel Disease Treatment Market, by Disease Indication**
- Ulcerative Colitis
- Crohn’s Disease

**Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel**
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy

**Global Inflammatory Bowel Disease Treatment Market, by End-User**
- Hospitals and Clinics
- Others

**Global Inflammatory Bowel Disease Treatment Market, by Region**

North America
- US
- Canada

South America
Europe
- Western Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe

Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific

Middle East & Africa
- UAE
- Saudi Arabia
- Oman
- Kuwait
- Qatar
- Rest of the Middle East & Africa

Intended Audience
- Pharmaceutical manufacturers and suppliers
- Medical research laboratories
- Research and development companies
- Market research and consulting service providers
- Potential investors

Contents:
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
  2.1 Definition
  2.2 Scope of the Study
  2.2.1 Research Objective
  2.2.2 Assumptions
  2.2.3 Limitations
Chapter 3. Research Methodology
  3.1 Introduction
  3.2 Primary Research
  3.3 Secondary Research
  3.4 Market Size Estimation
Chapter 4. Market Dynamics
  4.1 Drivers
  4.2 Restraints
  4.3 Opportunities
  4.4 Challenges
  4.5 Macroeconomic Indicators
  4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
  5.1 Porter’s Five Forces Analysis
    5.1.1 Bargaining Power of Suppliers
    5.1.2 Bargaining Power of Buyers
Chapter 6. Global Inflammatory Bowel Disease Treatment Market, by Drug Class

6.1 Introduction

6.2 TNF Inhibitors
Market Estimates & Forecast, by Region, 2018–2023

6.3 Aminosalicylates
Market Estimates & Forecast, by Region, 2018–2023

6.4 Immunomodulators
Market Estimates & Forecast, by Region, 2018–2023

6.5 Corticosteroids
Market Estimates & Forecast, by Region, 2018–2023

Chapter 7. Global Inflammatory Bowel Disease Treatment Market, by Disease Indication

7.1 Introduction

7.2 Ulcerative Colitis
Market Estimates & Forecast, by Region, 2018–2023

7.3 Crohn’s Disease
Market Estimates & Forecast, by Region, 2018–2023

Chapter 8. Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel

8.1 Introduction

8.2 Hospital Pharmacy
Market Estimates & Forecast, by Region, 2018–2023

8.3 Retail Pharmacy
Market Estimates & Forecast, by Region, 2018–2023

8.4 Online Pharmacy
Market Estimates & Forecast, by Region, 2018–2023

Chapter 9. Global Inflammatory Bowel Disease Treatment Market, by End-User

9.1 Introduction

9.2 Hospitals & Clinics
Market Estimates & Forecast, by Region, 2018–2023

9.3 Others
Market Estimates & Forecast, by Region, 2018–2023

Chapter 10. Global Inflammatory Bowel Disease Treatment Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa

Chapter 11. Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies

Chapter 12. Company Profiles
12.1 Abbott Laboratories
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Valeant Pharmaceuticals International
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Novartis AG
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Janssen Biotech, Inc.
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Alkem Laboratories Limited
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 AbbVie, Inc.
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 UCB Inc
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Takeda Pharmaceutical Company Limited
12.8.1 Overview
12.8.2 Product Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Biogen Inc.
12.9.1 Overview
12.9.2 Product Overview
12.9.3 Financials
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.10 Pfizer Inc.
12.10.1 Overview
12.10.2 Product Overview
12.10.3 Financials
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.11 Allergan plc.
12.11.1 Overview
12.11.2 Product Overview
12.11.3 Financials
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.12 Others
Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From the CEO's Viewpoint
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Predictions for the Inflammatory Bowel Disease Treatment Industry

Chapter 14. Appendix

LIST OF TABLES
Table 1 Global Inflammatory Bowel Disease Treatment Market Synopsis, 2018–2023
Table 2 Global Inflammatory Bowel Disease Treatment Market Estimates and Forecast, 2018–2023 (USD Million)
Table 3 Global Inflammatory Bowel Disease Treatment Market, by Region, 2018–2023 (USD Million)
Table 4 Global Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2018–2023 (USD Million)
Table 5 Global Inflammatory Bowel Disease Treatment Market, by Drug Class, 2018–2023 (USD Million)
Table 6 Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018–2023 (USD Million)
Table 7 Global Inflammatory Bowel Disease Treatment Market, by End-User, 2018–2023 (USD Million)
Table 8 North America: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2018–2023 (USD Million)
Table 9 North America: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2018–2023 (USD Million)
Table 10 North America: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018–2023 (USD Million)
Table 11 North America: Inflammatory Bowel Disease Treatment Market, by End-User, 2018–2023 (USD Million)
Table 12 US: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2018–2023 (USD Million)
Table 13 US: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2018–2023 (USD Million)
Table 14 US: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018–2023 (USD Million)
Table 15 US: Inflammatory Bowel Disease Treatment Market, by End-User, 2018–2023 (USD Million)
Table 16 Canada: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2018–2023 (USD Million)
Table 17 Canada: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2018–2023 (USD Million)
Table 18 Canada: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018–2023 (USD Million)
Table 19 Canada: Inflammatory Bowel Disease Treatment Market, by End-User, 2018–2023 (USD Million)
Table 20 South America: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2018–2023 (USD Million)
Table 21 South America: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2018–2023 (USD Million)
Table 22 South America: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018–2023 (USD Million)
Table 23 South America: Inflammatory Bowel Disease Treatment Market, by End-User, 2018–2023 (USD Million)
Table 24 Europe: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2018–2023 (USD Million)
Table 25 Europe: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2018–2023 (USD Million)
Table 26 Europe: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018–2023 (USD Million)
Table 27 Europe: Inflammatory Bowel Disease Treatment Market, by End-User, 2018–2023 (USD Million)
Table 28 Western Europe: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2018–2023 (USD Million)
Table 29 Western Europe: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2018–2023 (USD Million)
Table 30 Western Europe: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018–2023 (USD Million)
Table 31 Western Europe: Inflammatory Bowel Disease Treatment Market, by End-User, 2018–2023 (USD Million)
Table 32 Eastern Europe: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2018–2023 (USD Million)
Table 33 Eastern Europe: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2018–2023 (USD Million)
Table 34 Eastern Europe: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018–2023 (USD Million)
Table 35 Asia-Pacific: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2018–2023 (USD Million)
Table 36 Asia-Pacific: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2018–2023 (USD Million)
Table 37 Asia-Pacific: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018–2023 (USD Million)
Table 38 Asia-Pacific: Inflammatory Bowel Disease Treatment Market, by End-User, 2018–2023 (USD Million)
Table 39 Middle East & Africa: Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2018–2023 (USD Million)
Table 40 Middle East & Africa: Inflammatory Bowel Disease Treatment Market, by Drug Class, 2018–2023 (USD Million)
Table 41 Middle East & Africa: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018–2023 (USD Million)
Table 42 Middle East & Africa: Inflammatory Bowel Disease Treatment Market, by End-User, 2018–2023 (USD Million)

LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Global Inflammatory Bowel Disease Treatment Market
Figure 3 Segmentation Market Dynamics for Inflammatory Bowel Disease Treatment Market
Figure 4 Global Inflammatory Bowel Disease Treatment Market Share, by Disease Indication, 2016
Figure 5 Global Inflammatory Bowel Disease Treatment Market Share, by Drug Class, 2016
Figure 6 Global Inflammatory Bowel Disease Treatment Market Share, by Distribution Channel, 2016
Figure 7 Global Inflammatory Bowel Disease Treatment Market Share, by End-User, 2016
Figure 8 Global Inflammatory Bowel Disease Treatment Market Share, by Region, 2016
Figure 9 North America: Inflammatory Bowel Disease Treatment Market Share, by Country, 2016
Figure 10 Europe: Inflammatory Bowel Disease Treatment Market Share, by Country, 2016
Figure 11 Asia-Pacific: Inflammatory Bowel Disease Treatment Market Share, by Country, 2016
Figure 12 Middle East & Africa: Inflammatory Bowel Disease Treatment Market Share, by Country, 2016
Figure 13 Global Inflammatory Bowel Disease Treatment Market: Company Share Analysis, 2016 (%)
Figure 14 Abbott Laboratories: Key Financials
Figure 15 Abbott Laboratories: Segmental Revenue
Figure 16 Abbott Laboratories: Geographical Revenue
Figure 17 Thermo Fisher Scientific, Key Financials
Figure 18 Novartis AG: Segmental Revenue
Figure 19 Novartis AG: Geographical Revenue
Figure 20 Takeda Pharmaceutical Company Limited: Key Financials
Figure 21 Takeda Pharmaceutical Company Limited: Segmental Revenue
Figure 22 Takeda Pharmaceutical Company Limited: Geographical Revenue
Figure 23 Pfizer Inc.: Key Financials
Figure 24 Pfizer Inc.: Segmental Revenue
Figure 25 Pfizer Inc.: Geographical Revenue
Figure 26 Biogen Inc.: Key Financials
Figure 27 Biogen Inc.: Segmental Revenue
Figure 28 Biogen Inc.: Geographical Revenue
Figure 29 Valeant Pharmaceuticals International: Key Financials
Figure 30 Valeant Pharmaceuticals International: Segmental Revenue
Figure 31 Valeant Pharmaceuticals International: Geographical Revenue